Export financials
Amryt Pharma plc (AMYT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Amryt Pharma plc Financial Ratios 2021-2011 | AMYT
Annual Financial Ratios Amryt Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
2547.2 | -21.5 | - | - | - | - | - | - | - | - | - |
P/S |
11.4 | 12.3 | - | - | - | - | - | - | - | - | - |
EPS |
- | -0.7 | -0.8 | -0.7 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
2.89 B | 2.6 B | 328 M | 73.3 M | 69.8 M | 33.9 M | 504 K | 13.2 M | 842 K | 439 K | 43.4 K |
EBITDA per Share |
-0.16 | -0.29 | -0.67 | -0.39 | - | - | - | - | - | - | - |
EV/EBITDA |
-75.0 | -55.9 | -6.5 | -4.1 | - | - | - | - | - | - | - |
PEG |
- | -0.17 | - | - | - | - | - | - | - | - | - |
P/B |
7.1 | 34.0 | - | - | - | - | - | - | - | - | - |
P/CF |
163.9 | 83.5 | - | - | - | - | - | - | - | - | - |
ROE % |
0.28 | -158.03 | -47.79 | 824.64 | - | - | - | - | - | - | - |
ROA % |
0.12 | -19.48 | -11.95 | -37.73 | - | - | - | - | - | - | - |
ROCE % |
-5.86 | -10.67 | -11.88 | -26.23 | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.1 | 1.3 | 1.0 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Amryt Pharma plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | - | - | -0.66 | - | - | - | -0.83 | - | - | - | -0.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | -0.16 | - | - | - | -0.29 | - | - | - | -0.67 | - | - | - | -0.39 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-205.54 | -205.54 | -205.54 | -205.54 | 619.10 | 618.82 | 618.82 | 618.82 | -158.03 | - | - | - | -47.79 | - | - | - | 824.64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-31.31 | -31.31 | -31.31 | -31.31 | 0.12 | - | - | - | -19.48 | - | - | - | -11.95 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-28.41 | -28.41 | -28.41 | -28.41 | 459.47 | 465.33 | 465.33 | 465.33 | -10.67 | - | - | - | -11.88 | - | - | - | 487.88 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | 1.8 | - | - | - | 1.1 | - | - | - | 1.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Amryt Pharma plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
CytomX Therapeutics
CTMX
|
$ 2.72 | 2.23 % | $ 375 M | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.53 | 0.41 % | $ 5.86 M | ||
|
Cue Biopharma
CUE
|
$ 25.87 | 1.41 % | $ 2.45 B | ||
|
CEL-SCI Corporation
CVM
|
$ 2.06 | 15.73 % | $ 16.5 M | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 65.91 | 0.41 % | $ 7.92 M | ||
|
Daré Bioscience
DARE
|
$ 0.85 | 4.7 % | $ 9.5 M | ||
|
DBV Technologies S.A.
DBVT
|
$ 11.76 | 1.82 % | $ 1.64 B | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.27 | 0.85 % | $ 389 M | ||
|
Denali Therapeutics
DNLI
|
$ 20.67 | 0.38 % | $ 3.57 B | ||
|
Precision BioSciences
DTIL
|
$ 6.26 | 1.29 % | $ 80.3 M | ||
|
Dyadic International
DYAI
|
$ 0.44 | 0.49 % | $ 15.9 M | ||
|
Editas Medicine
EDIT
|
$ 2.57 | 0.19 % | $ 228 M | ||
|
Edesa Biotech
EDSA
|
$ 4.21 | 18.26 % | $ 23.9 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.5 | 4.73 % | $ 22.8 M | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 13.18 | 4.27 % | $ 281 K | ||
|
Entera Bio Ltd.
ENTX
|
$ 2.91 | 8.18 % | $ 134 M | ||
|
Equillium
EQ
|
$ 1.63 | 0.31 % | $ 93.4 M | ||
|
Eton Pharmaceuticals
ETON
|
$ 51.49 | 0.02 % | $ 1.39 B | ||
|
Evogene Ltd.
EVGN
|
$ 0.4 | 7.89 % | $ 3.15 M | ||
|
Exelixis
EXEL
|
$ 58.41 | 0.91 % | $ 15.9 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 3.27 | 3.32 % | $ 240 K | ||
|
Fate Therapeutics
FATE
|
$ 2.37 | 0.63 % | $ 282 M | ||
|
Fortress Biotech
FBIO
|
$ 2.14 | 1.38 % | $ 59.7 M | ||
|
Fennec Pharmaceuticals
FENC
|
$ 10.65 | 0.5 % | $ 304 M | ||
|
Foghorn Therapeutics
FHTX
|
$ 3.57 | 1.42 % | $ 225 M | ||
|
Fulcrum Therapeutics
FULC
|
$ 3.7 | 0.27 % | $ 234 M | ||
|
Galectin Therapeutics
GALT
|
$ 3.88 | 0.13 % | $ 248 M | ||
|
Geron Corporation
GERN
|
$ 1.23 | 0.81 % | $ 820 M | ||
|
Gilead Sciences
GILD
|
$ 149.05 | 0.85 % | $ 185 B | ||
|
Greenwich LifeSciences
GLSI
|
$ 18.05 | 2.07 % | $ 244 M | ||
|
Genmab A/S
GMAB
|
$ 35.67 | 0.3 % | $ 2.31 B | ||
|
Genprex
GNPX
|
$ 2.92 | 2.46 % | $ 2.72 M | ||
|
Gossamer Bio
GOSS
|
$ 11.85 | 2.33 % | $ 2.71 B | ||
|
GeoVax Labs
GOVX
|
$ 0.33 | 0.28 % | $ 316 K | ||
|
Grifols, S.A.
GRFS
|
$ 7.31 | 0.21 % | $ 4.97 B | ||
|
GlaxoSmithKline plc
GSK
|
$ 48.17 | 0.93 % | $ 195 B | ||
|
GT Biopharma
GTBP
|
$ 6.47 | 0.22 % | $ 35.7 M | ||
|
Halozyme Therapeutics
HALO
|
$ 110.4 | 0.1 % | $ 13.2 B | ||
|
Hutchison China MediTech Limited
HCM
|
$ 14.63 | 3.39 % | $ 12.6 B | ||
|
Harmony Biosciences Holdings
HRMY
|
$ 39.26 | 0.1 % | $ 2.26 B | ||
|
Heron Therapeutics
HRTX
|
$ 0.31 | 2.45 % | $ 51.7 M | ||
|
iBio
IBIO
|
$ 1.18 | 0.85 % | $ 123 M | ||
|
ImmuCell Corporation
ICCC
|
$ 9.8 | 0.61 % | $ 88.5 M | ||
|
IDEAYA Biosciences
IDYA
|
$ 38.42 | 1.48 % | $ 3.4 B | ||
|
InflaRx N.V.
IFRX
|
$ 1.8 | 0.54 % | $ 121 M | ||
|
Inhibikase Therapeutics
IKT
|
$ 2.06 | 1.73 % | $ 203 M | ||
|
Immutep Limited
IMMP
|
$ 4.65 | 0.21 % | $ 6.77 B | ||
|
Immunome
IMNM
|
$ 21.51 | 0.41 % | $ 1.88 B | ||
|
Immuron Limited
IMRN
|
$ 1.16 | 2.59 % | $ 268 M | ||
|
Immatics N.V.
IMTX
|
$ 8.78 | 2.57 % | $ 1.07 B |